Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

Slides:

Advertisements

Similar presentations

Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,

Advertisements

Pramlintide Acetate Safety Review Dragos Roman MD Center for Drug Evaluation and Research.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Methylphenidate Transdermal System (MTS): Safety Issues Robert Levin, M.D. Medical Officer Division of Psychiatry Products Center for Drug Evaluation and.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 ENTEREG ® (Alvimopan) Part 1: Efficacy and General Safety Evaluation Clinical Evaluation of NDA ENTEREG ® (Alvimopan) Part 1: Efficacy and General.

1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.

Safety & Efficacy Update on Approved TNF-Blocking Agents Jeffrey N. Siegel, M.D. OTRR, CBER / FDA Arthritis Advisory Committee March 4, 2003 Jeffrey N.

1 Lotronex ® Presentation to GI Advisory Committee June 27, 2000 Hugo E. Gallo-Torres MD, PHD Medical Team Leader DGICDP CDER, FDA.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

That is the problem!!!!  Acute colonic pseudo-obstruction (ACPO) is characterised by massive colonic dilation with symptoms and signs of colonic obstruction.

Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 ZELMAC (tegaserod) Presentation to GI Advisory Committee June 26, 2000 Raymond E. Joseph MD Medical Officer HFD-180.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.

A 1 Alosetron /26 Elizabeth B. Andrews, Ph.D., M.P.H. Director, Worldwide Epidemiology.

Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.

CI-1 Foradil ® (formoterol fumarate inhalation powder) FDA Advisory Committee Meeting July 13, 2005 FDA Advisory Committee Meeting July 13,

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.

VIOXX ™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001 Lourdes Villalba, M.D. DAAODP, CDER, FDA.

Post-Marketing AE Reports of Topical Calcineurin Inhibitors Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee Marilyn R. Pitts,

CI-1 Zelnorm ® (tegaserod maleate) Gastrointestinal Drugs Advisory Committee Meeting July 14, 2004 Gastrointestinal Drugs Advisory Committee Meeting July.

1 1 Zelnorm ® (tegaserod maleate) Advisory Committee Presentation Gastrointestinal Drugs July 14, 2004.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.

Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

A 2 Alosetron /26 Allen Mangel, M.D., Ph.D. International Director Gastroenterology International Product Development Leader, Alosetron Safety &

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

AprepitantAprepitant Division of Gastrointestinal and Coagulation Drug Products Division of Gastrointestinal and Coagulation Drug Products Center for Drug.

IN 1 NDA Gastrointestinal Advisory Committee Meeting Gaithersburg, Maryland June 26, 2000 Gastrointestinal Advisory Committee Meeting Gaithersburg,

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

OTC NSAID and ASA GI Bleeding Analysis of Spontaneous Reports Nonprescription Drugs Advisory Committee Meeting Joyce P. Weaver, Pharm.D. Office of Drug.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.

CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

27 June 2000Victor F. C. Raczkowski, M.D.1 Benefit-Risk Reevaluation of Marketed Drugs Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory.

Modafinil for the Treatment of ADHD Paul J. Andreason, MD Acting Deputy Director Division of Psychiatry Products Center for Drug Evaluation and Research,

Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.

OVERTURE FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Milton Packer, M.D., FACC Columbia University College of Physicians.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

1 Pain Arthritis Advisory Committee July 30, 2002 James Witter MD, PhD Division of Analgesics, Anti-Inflammatory & Ophthalmologic Drug Products HFD-550.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.

Drug Regulation in Controversy: Vioxx November 10, 2004 Sandra L. Kweder, M.D. Deputy Director, Office of New Drugs Center for Drug Evaluation and Research.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation Michael Camilleri, M.D., Rene Kerstens, M.Sc., An Rykx, Ph.D., and Lieve Vandeplassche,

Randomized Evaluation of Long-term anticoagulant therapY

Drugs for the treatment of irritable bowel syndrome (IBS)

Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events

Pediatric Inactivated Influenza Vaccine Safety VAERS Reports for Trivalent Inactivated Influenza Vaccine (TIV) in Infants/Toddlers Ann McMahon, MD, MS.

 INDICATIONS AND USAGE  DOSAGE AND ADMINISTRATION  DOSAGE FORMS AND STRENGTHS  WARNINGS AND PRECAUTIONS  ADVERSE REACTIONS  USE IN SPECIFIC POPULATIONS.

Presentation transcript:

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S Ann Corken Mackey, Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. July 14, 2004 Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S Ann Corken Mackey, Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. July 14, 2004 Center for Drug Evaluation and Research

Gastrointestinal Drugs Advisory Committee Meeting July 14, OverviewOverview Current Safety Issues Serious Consequences of Diarrhea hypotension syncope Abdominal and Pelvic Surgery Ischemic Colitis / Intestinal Ischemia Current Safety Issues Serious Consequences of Diarrhea hypotension syncope Abdominal and Pelvic Surgery Ischemic Colitis / Intestinal Ischemia

Gastrointestinal Drugs Advisory Committee Meeting July 14, Zelnorm ® (tegaserod) 5-HT 4 partial agonist Moderate 5-HT 1 receptor affinity Approved C-IBS dose: 6 mg BID Chronic Constipation dose: 6 mg BID 5-HT 4 partial agonist Moderate 5-HT 1 receptor affinity Approved C-IBS dose: 6 mg BID Chronic Constipation dose: 6 mg BID

Gastrointestinal Drugs Advisory Committee Meeting July 14, Post Marketing Experience April 27, 2004 Label Revision & Dear Doctor Letter WARNINGS Section: Serious Consequences of Diarrhea hypovolemia hypotension syncope PRECAUTIONS Section: Ischemic Colitis / Intestinal Ischemia Label Revision & Dear Doctor Letter WARNINGS Section: Serious Consequences of Diarrhea hypovolemia hypotension syncope PRECAUTIONS Section: Ischemic Colitis / Intestinal Ischemia

Gastrointestinal Drugs Advisory Committee Meeting July 14, Chronic Constipation Trials Similar AE Profile to C-IBS Trials

Gastrointestinal Drugs Advisory Committee Meeting July 14, Chronic Constipation Trials

Gastrointestinal Drugs Advisory Committee Meeting July 14, Zelnorm ® Safety Profile Post Marketing –MedWatch Program Clinical Trials –Chronic Constipation Trials –C-IBS Trials –Other GI Studies Post Marketing –MedWatch Program Clinical Trials –Chronic Constipation Trials –C-IBS Trials –Other GI Studies

Gastrointestinal Drugs Advisory Committee Meeting July 14, Post Marketing Serious Consequences of Diarrhea (n=22) Females (n=20) Males (n=2) –Range: 24 to 82 years –Mean Age: 56 years –Time to onset: 1 to 210 days –Hospitalized (n=15) –Described as Life Threatening (n=3) Dehydration (n=12) Abdominal pain (n=8) Hypotension(n=3) Electrolyte disorder(n=3) Shock(n=2) (Adverse Events not mutually exclusive) Females (n=20) Males (n=2) –Range: 24 to 82 years –Mean Age: 56 years –Time to onset: 1 to 210 days –Hospitalized (n=15) –Described as Life Threatening (n=3) Dehydration (n=12) Abdominal pain (n=8) Hypotension(n=3) Electrolyte disorder(n=3) Shock(n=2) (Adverse Events not mutually exclusive)

Gastrointestinal Drugs Advisory Committee Meeting July 14, Chronic Constipation Trials Diarrhea

Gastrointestinal Drugs Advisory Committee Meeting July 14, Chronic Constipation Trials Diarrhea

Gastrointestinal Drugs Advisory Committee Meeting July 14, Chronic Constipation Trials Diarrhea

Gastrointestinal Drugs Advisory Committee Meeting July 14, Post Marketing Hypotension 15 cases: Multiple confounding factors Case: PHEH2003US y/o female No PMH of hyper/hypotension, BP:138/80 prior to Zelnorm BP:75/60 after Zelnorm (2 weeks) 15 cases: Multiple confounding factors Case: PHEH2003US y/o female No PMH of hyper/hypotension, BP:138/80 prior to Zelnorm BP:75/60 after Zelnorm (2 weeks)

Gastrointestinal Drugs Advisory Committee Meeting July 14, Chronic Constipation Trials Hypotension Orthostatic Hypotension –Zelnorm 6mg BID11% –Zelnorm 2mg BID15% –Placebo12% Severe Diarrhea  Hypotension Orthostatic Hypotension –Zelnorm 6mg BID11% –Zelnorm 2mg BID15% –Placebo12% Severe Diarrhea  Hypotension

Gastrointestinal Drugs Advisory Committee Meeting July 14, SyncopeSyncope Post Marketing: 8 cases Multiple confounding factors Chronic Constipation Trials: 4 cases Zelnorm 6 mg BID (n=2) Placebo(n=2) Post Marketing: 8 cases Multiple confounding factors Chronic Constipation Trials: 4 cases Zelnorm 6 mg BID (n=2) Placebo(n=2)

Gastrointestinal Drugs Advisory Committee Meeting July 14, Selected Abdominal and Pelvic Adverse Events (Original Approval)

Gastrointestinal Drugs Advisory Committee Meeting July 14, Selected Abdominal and Pelvic Adverse Events Post Marketing: AERS Not designed to track common surgeries Post Marketing: AERS Not designed to track common surgeries

Gastrointestinal Drugs Advisory Committee Meeting July 14, Cholecystectomy Completed Clinical Trials

Gastrointestinal Drugs Advisory Committee Meeting July 14, Post Marketing GI Ischemic Events  2 million Rx * –April 15, 2004 Cutoff : 24 cases –Ischemic Colitis (n=20) –Other Intestinal Ischemia (n=4) –April 16 thru June 1, 2004: 9 cases –Ischemic Colitis (n=7) –Other Intestinal Ischemia (n=2) * IMS Projected Data through April 30, 2004  2 million Rx * –April 15, 2004 Cutoff : 24 cases –Ischemic Colitis (n=20) –Other Intestinal Ischemia (n=4) –April 16 thru June 1, 2004: 9 cases –Ischemic Colitis (n=7) –Other Intestinal Ischemia (n=2) * IMS Projected Data through April 30, 2004

Gastrointestinal Drugs Advisory Committee Meeting July 14, Post Marketing Ischemic Colitis (n=20) Females (n=19) Males (n=1) –Range: 26 to 82 years –Mean Age: 55 years –Time to onset: 1 to 398 days Treatment: IBS (n=16) Constipation (n=2) Postoperative Ileus (n=1) Unknown (n=1) Females (n=19) Males (n=1) –Range: 26 to 82 years –Mean Age: 55 years –Time to onset: 1 to 398 days Treatment: IBS (n=16) Constipation (n=2) Postoperative Ileus (n=1) Unknown (n=1)

Gastrointestinal Drugs Advisory Committee Meeting July 14, Post Marketing Ischemic Colitis (n=20) Outcomes –Hospitalization (n=13) –Surgery (n=1) –Death (n=1) –Outpatient treatment (n=7) Outcomes –Hospitalization (n=13) –Surgery (n=1) –Death (n=1) –Outpatient treatment (n=7)

Gastrointestinal Drugs Advisory Committee Meeting July 14, Post Marketing No Documented Risk Factors

Gastrointestinal Drugs Advisory Committee Meeting July 14, Post Marketing Other Intestinal Ischemia (n=4) Females (n=4) Males (n=0) –Ages: 41, 61, 66, 67 years –Mean Age: 59 years –Time to onset: 6 to 105 days –Hospitalized (n=4) –Surgery (n=3) –Death (n=3) Confounding medical conditions (n=4) Females (n=4) Males (n=0) –Ages: 41, 61, 66, 67 years –Mean Age: 59 years –Time to onset: 6 to 105 days –Hospitalized (n=4) –Surgery (n=3) –Death (n=3) Confounding medical conditions (n=4)

Gastrointestinal Drugs Advisory Committee Meeting July 14, Clinical Trials GI Ischemic Events  12,000 patients –Study Indications –Chronic Constipation –C-IBS –Other GI Studies Suspicious for GI Ischemia (n=0)  7000 patients exposed  3 months –Incidence no more than 1:2000 * *Based on Poisson Distribution  12,000 patients –Study Indications –Chronic Constipation –C-IBS –Other GI Studies Suspicious for GI Ischemia (n=0)  7000 patients exposed  3 months –Incidence no more than 1:2000 * *Based on Poisson Distribution

Gastrointestinal Drugs Advisory Committee Meeting July 14, ConclusionsConclusions Ischemic Colitis / Intestinal Ischemia: (n=24) < 49 years of age: (n=7) < 30 years of age: (n=2) No documented risk factors (n=5) Occurred on 1st Day of Therapy (n=3) Additional Cases since Labeling Change Ischemic Colitis / Intestinal Ischemia: (n=24) < 49 years of age: (n=7) < 30 years of age: (n=2) No documented risk factors (n=5) Occurred on 1st Day of Therapy (n=3) Additional Cases since Labeling Change

Gastrointestinal Drugs Advisory Committee Meeting July 14, ConclusionsConclusions Ischemic Colitis Background Incidence Novartis Higher background incidence in IBS patients FDA No increased background incidence in IBS ICD9 Code 564.1: sensitive, not specific Ischemic Colitis Background Incidence Novartis Higher background incidence in IBS patients FDA No increased background incidence in IBS ICD9 Code 564.1: sensitive, not specific

Gastrointestinal Drugs Advisory Committee Meeting July 14, ConclusionsConclusions Cross reactivity? Mechanism of action ? –Raynaud's phenomenon –5HT 1 mediated arterial spasm Mechanistic studies pending Cross reactivity? Mechanism of action ? –Raynaud's phenomenon –5HT 1 mediated arterial spasm Mechanistic studies pending

Gastrointestinal Drugs Advisory Committee Meeting July 14, ConclusionsConclusions Chronic Constipation Trials: No new Safety Issues Limited data in males Limited data in Patients  65 years Questionable risk/benefit  65 years Complications of Diarrhea Possible increased risk in elderly Appropriately labeled ? Chronic Constipation Trials: No new Safety Issues Limited data in males Limited data in Patients  65 years Questionable risk/benefit  65 years Complications of Diarrhea Possible increased risk in elderly Appropriately labeled ?

Gastrointestinal Drugs Advisory Committee Meeting July 14, ConclusionsConclusions Abdominal / Pelvic Surgery Phase IV studies pending Still unknown Ischemic Colitis Higher background incidence? Appropriately labeled ? Abdominal / Pelvic Surgery Phase IV studies pending Still unknown Ischemic Colitis Higher background incidence? Appropriately labeled ?

Gastrointestinal Drugs Advisory Committee Meeting July 14, QuestionsQuestions